Weave Communications Earnings Call Transcripts
Fiscal Year 2026
-
AI-powered engagement and payments solutions are driving strong growth, with revenue up 17% and free cash flow up 24%. New AI products and expanded verticals are accelerating upsell and market penetration, while operational leverage and profitability continue to improve.
Fiscal Year 2025
-
Delivered 17% revenue growth and record gross margin in 2025, with strong free cash flow and expanding AI-powered solutions. Specialty medical and payments segments led growth, while new partnerships and product launches position the company for continued momentum in 2026.
-
Q3 saw 17.1% revenue growth, record gross margin, and strong free cash flow, driven by AI-powered automation and expanding specialty medical and payments segments. Full-year guidance was raised, with continued investment in integrations and product innovation.
-
AI integration is driving workflow automation, payment modernization, and profitability for SMB healthcare practices, with significant growth potential in underpenetrated verticals and new markets. Financial targets include ARR growth to $500 million and expanded high-margin payment solutions.
-
Q2 2025 revenue grew 15.6% year-over-year to $58.5M, with record sales and strong free cash flow. Gross margin improved, TrueLark was acquired and integrated, and specialty medical became the second largest vertical. Full-year guidance was raised, with profitability set to improve.
-
The meeting covered director elections, auditor ratification, and corporate governance procedures. All proposals passed, with no questions from shareholders. Forward-looking statements were noted as subject to risks and uncertainties.
-
Q1 2025 revenue grew 18.3% year-over-year to $55.8M, with gross margin up 170 bps to 72.1%. Announced $35M acquisition of TrueLark to expand AI automation and addressable market, raising full-year revenue guidance to $236.8–239.8M.
Fiscal Year 2024
-
Revenue grew 20% in 2024 with record profitability and free cash flow, driven by strong specialty medical and payments growth. 2025 guidance anticipates continued double-digit growth, ongoing investments in payments, AI, and partnerships, and a CFO transition.
-
Q3 saw over 20% revenue growth, first-ever positive non-GAAP operating income, and gross margin expansion to 72.5%. Specialty medical led segment growth, while new platform launches and strategic partnerships fueled momentum. Raised full-year guidance and expect continued profitability.
-
Q2 revenue grew 21.4% year-over-year to $50.6 million, with gross margin up to 71.9% and first-ever positive Adjusted EBITDA. Specialty medical led growth, partnerships expanded, and full-year guidance was raised, reflecting strong execution and resilient demand.